Eli Lilly Delays FDA Filing for Retatrutide Weight-Loss Drug

Eli Lilly (LLY) announced that it will file for approval of its next-generation weight-loss drug, retatrutide, in 2027 after successfully completing two more trials. In clinical studies, retatrutide helped adults with diabetes or heart disease lose an average of 56 pounds, with some patients losing up to 20 percent of their weight. This delay in filing could impact Eli Lilly's market strategy and influence investor sentiment on the company's long-term prospects. Investors should be aware that the approval delay may affect stock performance in the near term.